Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation

Authors: Ibtehaj Al-Sharif, Adnane Remmal, Abdelilah Aboussekhra

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Breast cancer is a major health problem that threatens the lives of millions of women worldwide each year. Most of the chemotherapeutic agents that are currently used to treat this complex disease are highly toxic with long-term side effects. Therefore, novel generation of anti-cancer drugs with higher efficiency and specificity are urgently needed.

Methods

Breast cancer cell lines were treated with eugenol and cytotoxicity was measured using the WST-1 reagent, while propidium iodide/annexinV associated with flow cytometry was utilized in order to determine the induced cell death pathway. The effect of eugenol on apoptotic and pro-carcinogenic proteins, both in vitro and in tumor xenografts was assessed by immunoblotting. While RT-PCR was used to determine eugenol effect on the E2F1 and survivin mRNA levels. In addition, we tested the effect of eugenol on cell proliferation using the real-time cell electronic sensing system.

Results

Eugenol at low dose (2 μM) has specific toxicity against different breast cancer cells. This killing effect was mediated mainly through inducing the internal apoptotic pathway and strong down-regulation of E2F1 and its downstream antiapoptosis target survivin, independently of the status of p53 and ERα. Eugenol inhibited also several other breast cancer related oncogenes, such as NF-κB and cyclin D1. Moreover, eugenol up-regulated the versatile cyclin-dependent kinase inhibitor p21WAF1 protein, and inhibited the proliferation of breast cancer cells in a p53-independent manner. Importantly, these anti-proliferative and pro-apoptotic effects were also observed in vivo in xenografted human breast tumors.

Conclusion

Eugenol exhibits anti-breast cancer properties both in vitro and in vivo, indicating that it could be used to consolidate the adjuvant treatment of breast cancer through targeting the E2F1/survivin pathway, especially for the less responsive triple-negative subtype of the disease.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. Ca Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
Moulder S, Hortobagyi GN: Advances in the treatment of breast cancer. Clin Pharmacol Ther. 2008, 83 (1): 26-36. 10.1038/sj.clpt.6100449.CrossRefPubMed
3.
Davar D, Beumer JH, Hamieh L, Tawbi H: Role of PARP inhibitors in cancer biology and therapy. Curr med chem. 2012, 19 (23): 3907-3921. 10.2174/092986712802002464.CrossRefPubMedPubMedCentral
4.
Dona F, Chiodi I, Belgiovine C, Raineri T, Ricotti R, Mondello C, Scovassi AI: Poly (ADP-ribosylation) and neoplastic transformation: effect of PARP inhibitors. Curr pharm biotechnol. 2012, Epub ahead of print
5.
Craig W, Beck L: Phytochemicals: health protective effects. Can J Diet Pract Res. 1999, 60 (2): 78-84.PubMed
6.
Craig WJ: Phytochemicals: guardians of our health. J Am Diet Assoc. 1997, 97 (10 Suppl 2): S199-204.CrossRefPubMed
7.
Garg AK, Buchholz TA, Aggarwal BB: Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal. 2005, 7 (11–12): 1630-1647.CrossRefPubMed
8.
Mann J: Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer. 2002, 2 (2): 143-148. 10.1038/nrc723.CrossRefPubMed
9.
Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP, Gescher AJ: Dietary polyphenolic phytochemicals–promising cancer chemopreventive agents in humans? a review of their clinical properties. Int J Cancer. 2007, 120 (3): 451-458. 10.1002/ijc.22419.CrossRefPubMed
10.
Pramod K, Ansari SH, Ali J: Eugenol: a natural compound with versatile pharmacological actions. Nat prod commun. 2010, 5 (12): 1999-2006.PubMed
11.
Benencia F, Courreges MC: In vitro and in vivo activity of eugenol on human herpesvirus. Phytother Res. 2000, 14 (7): 495-500. 10.1002/1099-1573(200011)14:7<495::AID-PTR650>3.0.CO;2-8.CrossRefPubMed
12.
Sondak VK, Sabel MS, Mule JJ: Allogeneic and autologous melanoma vaccines: where have we been and where are we going?. Clin Cancer Res. 2006, 12 (7 Pt 2): 2337s-2341s.CrossRefPubMed
13.
Stich HF, Stich W, Lam PP: Potentiation of genotoxicity by concurrent application of compounds found in betel quid: arecoline, eugenol, quercetin, chlorogenic acid and Mn2+. Mutat Res. 1981, 90 (4): 355-363. 10.1016/0165-1218(81)90058-6.CrossRefPubMed
14.
Slamenova D, Horvathova E, Wsolova L, Sramkova M, Navarova J: Investigation of anti-oxidative, cytotoxic, DNA-damaging and DNA-protective effects of plant volatiles eugenol and borneol in human-derived HepG2, Caco-2 and VH10 cell lines. Mutat Res. 2009, 677 (1–2): 46-52.CrossRefPubMed
15.
Ghosh R, Nadiminty N, Fitzpatrick JE, Alworth WL, Slaga TJ, Kumar AP: Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity. J Biol Chem. 2005, 280 (7): 5812-5819.CrossRefPubMed
16.
Pisano M, Pagnan G, Loi M, Mura ME, Tilocca MG, Palmieri G, Fabbri D, Dettori MA, Delogu G, Ponzoni M, et al: Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol cancer. 2007, 6: 8-10.1186/1476-4598-6-8.CrossRefPubMedPubMedCentral
17.
Park BS, Song YS, Yee SB, Lee BG, Seo SY, Park YC, Kim JM, Kim HM, Yoo YH: Phospho-ser 15-p53 translocates into mitochondria and interacts with Bcl-2 and Bcl-xL in eugenol-induced apoptosis. Apoptosis. 2005, 10 (1): 193-200. 10.1007/s10495-005-6074-7.CrossRefPubMed
18.
Okada N, Hirata A, Murakami Y, Shoji M, Sakagami H, Fujisawa S: Induction of cytotoxicity and apoptosis and inhibition of cyclooxygenase-2 gene expression by eugenol-related compounds. Anticancer Res. 2005, 25 (5): 3263-3269.PubMed
19.
Manikandan P, Murugan RS, Priyadarsini RV, Vinothini G, Nagini S: Eugenol induces apoptosis and inhibits invasion and angiogenesis in a rat model of gastric carcinogenesis induced by MNNG. Life Sci. 2010, 86 (25–26): 936-941.CrossRefPubMed
20.
Al-Mohanna MA, Al-Khalaf HH, Al-Yousef N, Aboussekhra A: The p16INK4a tumor suppressor controls p21WAF1 induction in response to ultraviolet light. Nucleic Acids Res. 2007, 35 (1): 223-233.CrossRefPubMed
21.
Rowlands TM, Pechenkina IV, Hatsell S, Cowin P: Beta-catenin and cyclin D1: connecting development to breast cancer. Cell Cycle. 2004, 3 (2): 145-148.CrossRefPubMed
22.
Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999, 19 (8): 5785-5799.CrossRefPubMedPubMedCentral
23.
Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M: NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999, 19 (4): 2690-2698.CrossRefPubMedPubMedCentral
24.
Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008, 8 (1): 61-70. 10.1038/nrc2293.CrossRefPubMed
25.
Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA: Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem. 2004, 279 (39): 40511-40520. 10.1074/jbc.M404496200.CrossRefPubMed
26.
Lacroix M, Toillon RA, Leclercq G: p53 and breast cancer, an update. Endocr Relat Cancer. 2006, 13 (2): 293-325. 10.1677/erc.1.01172.CrossRefPubMed
27.
Vuaroqueaux V, Urban P, Labuhn M, Delorenzi M, Wirapati P, Benz CC, Flury R, Dieterich H, Spyratos F, Eppenberger U, et al: Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res. 2007, 9 (3): R33-10.1186/bcr1681.CrossRefPubMedPubMedCentral
28.
Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY: E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res Treat. 2003, 82 (1): 11-16. 10.1023/B:BREA.0000003843.53726.63.CrossRefPubMed
29.
Jha K, Shukla M, Pandey M: Survivin expression and targeting in breast cancer. Surgical oncology. 2012, 21 (2): 125-131. 10.1016/j.suronc.2011.01.001.CrossRefPubMed
30.
Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH: Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010, 176 (6): 2911-2920. 10.2353/ajpath.2010.091125.CrossRefPubMedPubMedCentral
31.
Carey L, Winer E, Viale G, Cameron D, Gianni L: Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol. 2010, 7 (12): 683-692. 10.1038/nrclinonc.2010.154.CrossRefPubMed
32.
Iaquinta PJ, Lees JA: Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol. 2007, 19 (6): 649-657. 10.1016/j.ceb.2007.10.006.CrossRefPubMedPubMedCentral
33.
Dotto GP: p21(WAF1/Cip1): more than a break to the cell cycle?. Biochim Biophys Acta. 2000, 1471 (1): M43-56.PubMed
34.
Gartel AL, Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002, 1 (8): 639-649.PubMed
35.
Hickman ES, Moroni MC, Helin K: The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev. 2002, 12 (1): 60-66. 10.1016/S0959-437X(01)00265-9.CrossRefPubMed
36.
Stanelle J, Putzer BM: E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol Med. 2006, 12 (4): 177-185. 10.1016/j.molmed.2006.02.002.CrossRefPubMed
37.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al: Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 2006, 295 (21): 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed
38.
Cao Y, Karin M: NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2003, 8 (2): 215-223. 10.1023/A:1025905008934.CrossRefPubMed
39.
Haffner MC, Berlato C, Doppler W: Exploiting our knowledge of NF-kappaB signaling for the treatment of mammary cancer. J Mammary Gland Biol Neoplasia. 2006, 11 (1): 63-73. 10.1007/s10911-006-9013-5.CrossRefPubMed
40.
Van Waes C: Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res. 2007, 13 (4): 1076-1082. 10.1158/1078-0432.CCR-06-2221.CrossRefPubMed
41.
Lee CH, Jeon YT, Kim SH, Song YS: NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 2007, 29 (1): 19-35. 10.1002/biof.5520290103.CrossRefPubMed
42.
Manikandan P, Vinothini G, Vidya Priyadarsini R, Prathiba D, Nagini S: Eugenol inhibits cell proliferation via NF-kappaB suppression in a rat model of gastric carcinogenesis induced by MNNG. Invest New Drugs. 2011, 29 (1): 110-117. 10.1007/s10637-009-9345-2.CrossRefPubMed
43.
Paul S, Dey A: Wnt signaling and cancer development: therapeutic implication. Neoplasma. 2008, 55 (3): 165-176.PubMed
44.
Prasad CP, Gupta SD, Rath G, Ralhan R: Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression. Oncology. 2007, 73 (1–2): 112-117.CrossRefPubMed
45.
King TD, Suto MJ, Li Y: The wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem. 2012, 113 (1): 13-18. 10.1002/jcb.23350.CrossRefPubMed
46.
Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B, Bartek J: Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res. 1995, 55 (4): 949-956.PubMed
47.
Yang C, Trent S, Ionescu-Tiba V, Lan L, Shioda T, Sgroi D, Schmidt EV: Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. Cancer Res. 2006, 66 (24): 11649-11658. 10.1158/0008-5472.CAN-06-1645.CrossRefPubMed
Metadata
Title
Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation
Authors
Ibtehaj Al-Sharif
Adnane Remmal
Abdelilah Aboussekhra
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-600

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up

Research article

Incidence of pneumonia and risk factors among patients with head and neck cancer undergoing radiotherapy

Research article

Effects of Δ40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53

Research article

Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors

Research article

Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway

Research article

Quantitative expression analysis and prognostic significance of the BCL2-associated Xgene in nasopharyngeal carcinoma: a retrospective cohort study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits